Bristol Myers Squibb Company $BMY Shares Acquired by Vontobel Holding Ltd.

Posted by Geri Gentry on Aug 15th, 2026

Vontobel Holding Ltd. increased its stake in Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 4.3% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 725,587 shares of the biopharmaceutical company’s stock after purchasing an additional 29,767 shares during the period. Vontobel Holding Ltd.’s holdings in Bristol Myers Squibb were worth $41,808,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in BMY. Norges Bank bought a new stake in Bristol Myers Squibb in the fourth quarter valued at $1,947,272,000. AQR Capital Management LLC boosted its holdings in shares of Bristol Myers Squibb by 172.6% during the fourth quarter. AQR Capital Management LLC now owns 25,796,905 shares of the biopharmaceutical company’s stock valued at $1,391,485,000 after acquiring an additional 16,332,924 shares during the period. Bank of New York Mellon Corp grew its position in shares of Bristol Myers Squibb by 47.0% during the fourth quarter. Bank of New York Mellon Corp now owns 24,495,875 shares of the biopharmaceutical company’s stock worth $1,321,308,000 after acquiring an additional 7,837,485 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Bristol Myers Squibb by 13.1% in the 4th quarter. Geode Capital Management LLC now owns 52,638,346 shares of the biopharmaceutical company’s stock worth $2,837,026,000 after acquiring an additional 6,084,046 shares during the period. Finally, Man Group plc lifted its position in Bristol Myers Squibb by 280.4% in the 2nd quarter. Man Group plc now owns 7,465,845 shares of the biopharmaceutical company’s stock valued at $345,594,000 after purchasing an additional 5,503,391 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts have issued reports on BMY shares. JPMorgan Chase & Co. boosted their target price on shares of Bristol Myers Squibb from $67.00 to $73.00 and gave the company an “overweight” rating in a research note on Friday, July 31st. Royal Bank Of Canada raised their price target on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the company a “sector perform” rating in a research note on Friday, July 31st. Weiss Ratings raised Bristol Myers Squibb from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, July 30th. Wells Fargo & Company set a $65.00 price objective on Bristol Myers Squibb and gave the stock an “equal weight” rating in a research report on Friday, July 31st. Finally, BMO Capital Markets reissued a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, July 27th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Bristol Myers Squibb currently has a consensus rating of “Moderate Buy” and a consensus price target of $66.06.

View Our Latest Stock Report on Bristol Myers Squibb

Bristol Myers Squibb Stock Performance

BMY stock opened at $63.86 on Friday. The company has a 50-day simple moving average of $59.56 and a 200 day simple moving average of $58.97. The company has a market capitalization of $130.45 billion, a P/E ratio of 14.07, a PEG ratio of 0.17 and a beta of 0.22. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $68.10.

Bristol Myers Squibb (NYSE:BMY – Get Free Report) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.60 by $0.44. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The firm had revenue of $12.97 billion for the quarter, compared to analysts’ expectations of $11.74 billion. During the same quarter last year, the company earned $1.46 EPS. Bristol Myers Squibb’s quarterly revenue was up 5.7% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Sell-side analysts predict that Bristol Myers Squibb Company will post 6.96 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 2nd were paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.9%. The ex-dividend date was Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 55.51%.

Trending Headlines about Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

Positive Sentiment: The U.S. FDA granted accelerated approval to ZENBEXUS, Bristol Myers Squibb’s first CELMoD therapy, in combination with daratumumab, hyaluronidase-fihj and dexamethasone for multiple myeloma patients as early as first relapse. The approval is strategically important because CELMoD drugs could help extend and rejuvenate the company’s important blood-cancer franchise. Bristol Myers wins milestone FDA approval of myeloma drug acquired from Celgene
Positive Sentiment: Zacks Research raised its Bristol Myers Squibb EPS outlook for fiscal 2027 to $6.20 from $5.93. It also increased estimates for the fourth quarter of 2026, the first and second quarters of 2027, and the first two quarters of 2028, suggesting improved analyst expectations for earnings momentum.
Positive Sentiment: The company expanded its kidney-disease pipeline with a Phase 1 study of golcadomide, providing another potential long-term growth opportunity beyond its established oncology products. Bristol-Myers Squibb expands kidney pipeline with new golcadomide renal study
Neutral Sentiment: Rumors of a potential AstraZeneca-Bristol Myers Squibb merger have generated investor concern. Although a transaction could create a sizable oncology-focused pharmaceutical company, the strategic, financial and execution risks remain uncertain, and no deal was confirmed. Reported AstraZeneca-Bristol Myers Squibb megamerger
Negative Sentiment: A federal appeals court revived a $6.7 billion lawsuit alleging Bristol Myers Squibb delayed approval of drugs acquired through Celgene, including Breyanzi. The case could create substantial financial liability and legal uncertainty. Lawsuit against Bristol Myers over delayed cancer drug is revived

Bristol Myers Squibb Company Profile

(Free Report)

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.